Cargando…

Improving Antibacterial Activity of a HtrA Protease Inhibitor JO146 against Helicobacter pylori: A Novel Approach Using Microfluidics-Engineered PLGA Nanoparticles

Nanoparticle drug delivery systems have emerged as a promising strategy for overcoming limitations of antimicrobial drugs such as stability, bioavailability, and insufficient exposure to the hard-to-reach bacterial drug targets. Although size is a vital colloidal feature of nanoparticles that govern...

Descripción completa

Detalles Bibliográficos
Autores principales: Hwang, Jimin, Mros, Sonya, Gamble, Allan B., Tyndall, Joel D. A., McDowell, Arlene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875321/
https://www.ncbi.nlm.nih.gov/pubmed/35214080
http://dx.doi.org/10.3390/pharmaceutics14020348
_version_ 1784657885459906560
author Hwang, Jimin
Mros, Sonya
Gamble, Allan B.
Tyndall, Joel D. A.
McDowell, Arlene
author_facet Hwang, Jimin
Mros, Sonya
Gamble, Allan B.
Tyndall, Joel D. A.
McDowell, Arlene
author_sort Hwang, Jimin
collection PubMed
description Nanoparticle drug delivery systems have emerged as a promising strategy for overcoming limitations of antimicrobial drugs such as stability, bioavailability, and insufficient exposure to the hard-to-reach bacterial drug targets. Although size is a vital colloidal feature of nanoparticles that governs biological interactions, the absence of well-defined size control technology has hampered the investigation of optimal nanoparticle size for targeting bacterial cells. Previously, we identified a lead antichlamydial compound JO146 against the high temperature requirement A (HtrA) protease, a promising antibacterial target involved in protein quality control and virulence. Here, we reveal that JO146 was active against Helicobacter pylori with a minimum bactericidal concentration of 18.8–75.2 µg/mL. Microfluidic technology using a design of experiments approach was utilized to formulate JO146-loaded poly(lactic-co-glycolic) acid nanoparticles and explore the effect of the nanoparticle size on drug delivery. JO146-loaded nanoparticles of three different sizes (90, 150, and 220 nm) were formulated with uniform particle size distribution and drug encapsulation efficiency of up to 25%. In in vitro microdilution inhibition assays, 90 nm nanoparticles improved the minimum bactericidal concentration of JO146 two-fold against H. pylori compared to the free drug alone, highlighting that controlled engineering of nanoparticle size is important in drug delivery optimization.
format Online
Article
Text
id pubmed-8875321
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88753212022-02-26 Improving Antibacterial Activity of a HtrA Protease Inhibitor JO146 against Helicobacter pylori: A Novel Approach Using Microfluidics-Engineered PLGA Nanoparticles Hwang, Jimin Mros, Sonya Gamble, Allan B. Tyndall, Joel D. A. McDowell, Arlene Pharmaceutics Article Nanoparticle drug delivery systems have emerged as a promising strategy for overcoming limitations of antimicrobial drugs such as stability, bioavailability, and insufficient exposure to the hard-to-reach bacterial drug targets. Although size is a vital colloidal feature of nanoparticles that governs biological interactions, the absence of well-defined size control technology has hampered the investigation of optimal nanoparticle size for targeting bacterial cells. Previously, we identified a lead antichlamydial compound JO146 against the high temperature requirement A (HtrA) protease, a promising antibacterial target involved in protein quality control and virulence. Here, we reveal that JO146 was active against Helicobacter pylori with a minimum bactericidal concentration of 18.8–75.2 µg/mL. Microfluidic technology using a design of experiments approach was utilized to formulate JO146-loaded poly(lactic-co-glycolic) acid nanoparticles and explore the effect of the nanoparticle size on drug delivery. JO146-loaded nanoparticles of three different sizes (90, 150, and 220 nm) were formulated with uniform particle size distribution and drug encapsulation efficiency of up to 25%. In in vitro microdilution inhibition assays, 90 nm nanoparticles improved the minimum bactericidal concentration of JO146 two-fold against H. pylori compared to the free drug alone, highlighting that controlled engineering of nanoparticle size is important in drug delivery optimization. MDPI 2022-02-01 /pmc/articles/PMC8875321/ /pubmed/35214080 http://dx.doi.org/10.3390/pharmaceutics14020348 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Hwang, Jimin
Mros, Sonya
Gamble, Allan B.
Tyndall, Joel D. A.
McDowell, Arlene
Improving Antibacterial Activity of a HtrA Protease Inhibitor JO146 against Helicobacter pylori: A Novel Approach Using Microfluidics-Engineered PLGA Nanoparticles
title Improving Antibacterial Activity of a HtrA Protease Inhibitor JO146 against Helicobacter pylori: A Novel Approach Using Microfluidics-Engineered PLGA Nanoparticles
title_full Improving Antibacterial Activity of a HtrA Protease Inhibitor JO146 against Helicobacter pylori: A Novel Approach Using Microfluidics-Engineered PLGA Nanoparticles
title_fullStr Improving Antibacterial Activity of a HtrA Protease Inhibitor JO146 against Helicobacter pylori: A Novel Approach Using Microfluidics-Engineered PLGA Nanoparticles
title_full_unstemmed Improving Antibacterial Activity of a HtrA Protease Inhibitor JO146 against Helicobacter pylori: A Novel Approach Using Microfluidics-Engineered PLGA Nanoparticles
title_short Improving Antibacterial Activity of a HtrA Protease Inhibitor JO146 against Helicobacter pylori: A Novel Approach Using Microfluidics-Engineered PLGA Nanoparticles
title_sort improving antibacterial activity of a htra protease inhibitor jo146 against helicobacter pylori: a novel approach using microfluidics-engineered plga nanoparticles
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875321/
https://www.ncbi.nlm.nih.gov/pubmed/35214080
http://dx.doi.org/10.3390/pharmaceutics14020348
work_keys_str_mv AT hwangjimin improvingantibacterialactivityofahtraproteaseinhibitorjo146againsthelicobacterpylorianovelapproachusingmicrofluidicsengineeredplgananoparticles
AT mrossonya improvingantibacterialactivityofahtraproteaseinhibitorjo146againsthelicobacterpylorianovelapproachusingmicrofluidicsengineeredplgananoparticles
AT gambleallanb improvingantibacterialactivityofahtraproteaseinhibitorjo146againsthelicobacterpylorianovelapproachusingmicrofluidicsengineeredplgananoparticles
AT tyndalljoelda improvingantibacterialactivityofahtraproteaseinhibitorjo146againsthelicobacterpylorianovelapproachusingmicrofluidicsengineeredplgananoparticles
AT mcdowellarlene improvingantibacterialactivityofahtraproteaseinhibitorjo146againsthelicobacterpylorianovelapproachusingmicrofluidicsengineeredplgananoparticles